Some of the Main Key Players Covered in the Diabetes Drugs Market Report

Johnson and Johnson

Bayer Pharmaceuticals

Novo Nordisk

Sanofi

Merck

Eli Lilly and Company

AstraZeneca

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim

Novartis

North America Expected to Dominate the Market

North America is expected to hold a large chunk of the Diabetes Drugs Market share in the forecast period. This evaluation is based on the region’s revenue generation of USD 23,965.5 million in 2018. Moreover, rising prevalence of diabetes in the US is encouraging companies to develop novel and affordable drugs for the patients.

Growing awareness among the people regarding diabetes and anti-diabetic drugs in North America will aid growth of the global diabetes drugs market , North America is expected to be followed by Europe in terms of market share and revenue generation during the forecast period

Key Segmentation for Diabetes Drugs Market

By Drug Class

Insulin

DPP-4 Inhibitors

GLP-1 Receptor Agonists

SGLT2 Inhibitors

By Diabetes Type

Type 1

Type 2

By Route of Administration

Oral

Subcutaneous

Intravenous

By Distribution Channel

Online pharmacies

Hospital Pharmacies

Retail Pharmacies

By Geography

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Rising Demand for Insulin Treatments to Surge the Market

Insulin provides the one of the most efficient treatment methods for diabetes. As a result, there is a growing demand for low-cost insulin treatments, especially to combat Type 2 diabetes. The rapidly rising insulin segment is, therefore, expected to boost the global diabetes drugs market during the forecast period. This has also encouraged private and public investments in research and development, which, in turn, will accelerate diabetes drugs market growth. For example, recently, a rapid-acting, low-cost insulin called Lispro was launched in its generic form by Eli Lilly and Company in the US.

Market Competition Set to Intensify

Key players are increasing their investments in research and development activities and launching new products to maintain their competitive edge. For example, in July 2019, the National Institute for Health and Care Excellence cleared Forxiga for treating Type 1 diabetes in England and Wales. The drug has been developed jointly by Bristol-Myers Squibb and AstraZeneca. The global diabetes drug market is expected to grow as a result.

Fortune Business Insights identifies some key players in the Diabetes Drugs Market which include Johnson and Johnson Services, Eli Lilly and Company, AstraZeneca, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Sanofi, and a few others.

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.